Neuroprotective Effects of Conditioned Medium of Mesenchymal Stem Cells (MSC-CM) as a Therapy for Ischemic Stroke Recovery: A Systematic Review

• Published in: Neurochemical research 2023-05, Vol.48 (5), p.1280-1292
• Main Authors: Behzadifard, Mahin, Aboutaleb, Nahid, Dolatshahi, Mojtaba, Khorramizadeh, Maryam, Mirshekari Jahangiri, Hamzeh, Kord, Zeynab, Nazarinia, Donya
• Format: Article
• Language: English
• Subjects: Animals; Biochemistry; Biomedical and Life Sciences; Biomedicine; Cell Biology; Cerebral blood flow; Clinical trials; Culture Media, Conditioned - metabolism; Culture Media, Conditioned - pharmacology; Disease Models, Animal; Humans; Infarction, Middle Cerebral Artery - metabolism; Ischemia; Ischemic Stroke - metabolism; Mesenchymal Stem Cell Transplantation - methods; Mesenchymal stem cells; Mesenchymal Stem Cells - metabolism; Neurochemistry; Neurology; Neuroprotection; Neuroprotective Agents - pharmacology; Neurosciences; Occlusion; Paracrine signalling; Recovery; Recovery of function; Review; Stem cells; Stroke; Stroke - metabolism; Systematic review; Therapy
• ISSN: 0364-3190; 1573-6903
• DOI: 10.1007/s11064-022-03848-x

It has been reported that the therapeutic potential of stem cells is mainly mediated by their paracrine factors. In order to identify the effects of conditioned medium of mesenchymal stem cells (MSC-CM) against stroke, a systematic review was conducted. We searched PubMed, Scopus, and ISI Web of Science databases for all available articles relevant to the effects of MSC-CM against the middle cerebral artery occlusion (MCAO) model of ischemic stroke until August 2022. The quality of the included studies was evaluated using The STAIR scale. During the systematic search, a total of 356 published articles were found. A total of 15 datasets were included following screening for eligibility. The type of cerebral ischemia was the MCAO model and CM was obtained from MSCs. The results showed that the therapeutic time window can be considered a crucial factor when researchers use MSC-CM for stroke therapy. In addition, MSC-CM therapy contributes to functional recovery and reduces infarct volume after stroke by targeting different cellular signaling pathways. Our findings showed that MSC-CM therapy has the ability to improve functional recovery and attenuate brain infarct volume after ischemic stroke in preclinical studies. We hope our study accelerates needed progress towards clinical trials.